title: [The role of telmisartan in the treatment of metabolic syndrome].
abstract: OBJECTIVE
  To evaluate telmisartan effects on 24-h blood pressure profile, sensitivity to insulin, carbohydrate and lipid metabolism in patients with metabolic syndrome (MS) and arterial hypertension (AH).
  
  
  METHODS
  Twenty patients with MS and AH of the degree I-II received telmisartan in a dose 80 mg/day. 24-h BP monitoring, tests for total cholesterol, HDLP, LDLP cholesterol, triglycerides, glucose, glucose tolerance test were made before and 24 weeks after the treatment.
  
  
  RESULTS
  Telmisartan reduced all the study parameters of blood pressure, body mass, fasting and post-prandial hyperglycemia, postprandial hyperinsulinemia. Telmisartan raised peripheral tissue sensitivity to insulin, normalized phases of insulin secretion. Total cholesterol, LDLP cholesterol diminished while HDLP went up.
  
  
  CONCLUSIONS
  Telmisartan has a specific ability to partially activate receptors stimulating proliferation of peroxisomes and improve regulation of carbohydrate and lipid metabolism, to reduce body mass.
authors.forename: V B
authors.initials: VB
authors.lastname: Mychka
authors.forename: D E
authors.initials: DE
authors.lastname: Duishvili
authors.forename: K M
authors.initials: KM
authors.lastname: Mamyrbaeva
authors.forename: V P
authors.initials: VP
authors.lastname: Masenko
authors.forename: I E
authors.initials: IE
authors.lastname: Chazova
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D047495:PPAR gamma / Q000097:blood; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin; D047495:PPAR gamma; D002784:Cholesterol; D000077333:Telmisartan